2024-517963-21-00招募中3 期
Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment-resistant depression: a randomized controlled trial (DARE-Trial) - A multicenter, randomized, double-blind, placebo-controlled trial with group sequential design
Charite Universitaetsmedizin Berlin KöR8 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2025年11月4日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 320
- 试验地点
- 8
- 主要终点
- Change score from baseline to week 6 in Montgomery-Asberg-Depression Rating Scale (MADRS)
研究概览
简要总结
To determine whether add-on 100 mg/d DHEA to continued standard antidepressant medication improves depression to a greater extent than add-on placebo in subjects with treatment-resistant depression
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Patient provided written informed consent
- •The patient is capable of giving consent (has sufficient knowledge of German and clearly understands the nature, significance and scope, including risks, of the medical procedure)
- •The patients is aged between 18 and 75 years (≥ 18 and ≤ 75)
- •The patient has an episode of major depression according to DSM 5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition)
- •The patient has treatment-resistant depression (TRD), defined as non-response to at least one 4-week antidepressant treatment trial (including the current treatment) in the index episode (corresponding to level 1 resistance to treatment failure according to the Maudsley staging method)
- •The patient has a Montgomery-Asberg Depression Rating Scale (MADRS) score of ≥ 20
- •The patient is receiving antidepressant medication (SSRI or SNRI or tricyclic antidepressant or mirtazapine or bupropion) for at least 4 weeks, the dosage is at least at the approved minimum therapeutic dosage and has been unchanged for at least 14 days prior to screening visit.
- •The patient had less than three (<3) treatment attempts with antidepressants in the current MDE (current treatment attempts not included).
排除标准
- •The patient has current clinically significant suicidal ideation with intent, corresponding to a score of 4 or 5 for ideation on the C-SSRS, or a suicidal attempt within the past 6 months, as indicated by the C-SSRS at screening visit
- •The patient is pregnant or breastfeeding.
- •The patient of childbearing age shows an unwillingness to use an effective contraceptive method (defined as a Pearl Index < 1)
- •The patient fulfills the criteria for psychotic depression according to DSM-5
- •The patient currently has or has a history of venous thromboembolism (VTE) (deep vein thrombosis, pulmonary embolism)
- •The patient currently has or has a history of arterial thromboembolic disease (e.g. angina pectoris, myocardial infarction, stroke)
- •The patient has a thrombophilic disease (e.g. protein C, protein S or antithrombin deficiency)
- •The patient has porphyria
- •The patient has clinically significant untreated hypothyroidism
- •The patient has clinically significant abnormalities in the 12-lead ECG (e.g. prolongation of the QTc interval ≥ 500 ms) as performed during screening visit
- •The patient is a vulnerable person (defined as: persons deprived their liberty, confined to an institution by court or administrative order, persons that may have Insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests, or unable to explicitly give consent)
- •The patient has or has had sex hormone-dependent cancer (e.g. breast cancer, ovarian cancer, endometrial cancer, prostate cancer)
- •The patient might be dependent on representative of the sponsor, the investigator or the trial site
- •The patient is currently participating in another interventional clinical trial.
- •The patient's laboratory values show clinically significant abnormalities
- •The patient meets the criteria for schizophrenia, schizoaffective disorder or bipolar disorder in M.I.N.I according to DSM-5
- •The patient currently has liver disease with liver-specific levels outside the age- and gender-specific reference intervals [elevations of GOT or GPT above 3 times the upper normal value (ULN)]
- •The patient meets the criteria for a dependency disorder in the M.I.N.I. for DSM-5
- •The patient has dementia or moderate to severe cognitive impairment.
- •The Patient is currently taking DHEA or has taken it within the last 14 days prior to screening visit.
- •The patients is currently taking hormone replacement therapy with sex hormones (other than contraceptives)
- •The patient has undiagnosed genital bleeding
- •The patient is allergic or has contraindication to DHEA or lactulose and cellulose
- •The patient has untreated endometrial hyperplasia
- •The patient has diagnosis of prostatic hyperplasia.
- •The patient has a medical history of liver failure and/or bilirubin above 3 times the normal range and reduced total protein.
- •The patient has previous diagnosis of chronic kidney disease stage G3b (or higher) or GFR < 30 ml/min.
- •The Patient is taking antidepressants other than those listed as inclusion criterion (SSRI, SNRI, tricyclic antidepressants, bupropion, mirtazapine)
- •The patient is taking psychotropic medication, e.g. antipsychotics, anticonvulsants, lithium or Johannis herbs. Allowed substances include benzodiazepines, non-benzodiazepines (Zopiclon, Zolpidem or Eszopiclon) and antidepressants listed under inclusion criteria.
- •The patient is using non-selective, irreversible MAO inhibitors (e.g. tranylcypromine) or selective, reversible MAO-A inhibitors (e.g. moclobemide) or the reversible non-selective MAO inhibitor linezolid
- •The patient has insulin-dependent diabetes mellitus
- •The patient has an untreated and unstable general medical condition (e.g. hypertension with end organ damage or hypertensive derailment)
结局指标
主要结局
Change score from baseline to week 6 in Montgomery-Asberg-Depression Rating Scale (MADRS)
Change score from baseline to week 6 in Montgomery-Asberg-Depression Rating Scale (MADRS)
次要结局
- Response, defined as 50% MADRS score reduction from baseline; Remission, defined as MADRS score <10
- Changes in BDI-II from baseline to week 6, CGI-S, CGI-I, PGIC, and SOFAS will be determined, and EuroQol-5 with MCID as well as ASEX will also be collected
- Change in glucose, glycosylated hemoglobin (HbA1c), total, HDL- and LDL-cholesterol, C-reactive protein (CRP), and interleukin-6 levels from baseline to week 6
- Safety endpoints of AE, tolerability and acceptability
研究者
Christian Otte
Scientific
Charite Universitaetsmedizin Berlin KöR
研究点 (8)
Loading locations...
相似试验
招募中
2 期
Pharmacologic treatment augmentation in chronic depression
“randomized, controlled, double blinded, phase II study”2024-512478-86-00Universitaetsklinikum Tuebingen AöR60
招募中
3 期
A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD)2024-513019-29-00Mylan Inc.600
招募中
2 期
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderMajor Depressive DisorderNCT07276997AbbVie195
招募中
3 期
The DEXA-PSYCH Study: Dexamethasone Repurposing for Moderate to Severe Depression - A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled TrialDepression2022-501428-45-00Region Hovedstadens Psykiatriske300
进行中（未招募）
不适用
A Clinical Study Evaluating the Efficacy and Safety of CreNeuriS CNS Herbal Nutrition Capsules for Participants With Mild Depressive Disorder Comorbid With Anxiety DisorderNCT07295444Second Affiliated Hospital of Nanchang University30